AGIO
AGIOS PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$34.90
+11.43%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$31.61
From 52W high−23.28%
Volume1.97M
Market cap$2.08B
P/E (TTM)—
P/S (TTM)21.2x
Div yield—
Key dataOct 19, 2026
Open
$31.61
From 52W high
−23.28%
Volume
1.97M
Market cap
$2.08B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.6x
P/E (TTM)
—
RSI (14)
56.2
MomentumView details →
1D Return
+11.43%
YTD Return
+23.62%
SummaryUpdated Jun 1, 2026
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is a biopharmaceutical company founded in 2007 and headquartered in Cambridge, Massachusetts. The company went public in July 2013 and specializes in discovering and developing medicines targeting cellular metabolism and adjacent areas of biology. Agios has successfully commercialized its first product, PYRUKYND (mitapivat), for treating rare blood disorders, and maintains a robust pipeline of investigational therapies for various hemolytic anemias and other metabolic conditions.
Similar companies
Latest newsMore news →
Assenagon Asset Management S.A. increased its stake in Agios Pharmaceuticals, Inc. by 54.8% during the second quarter, acquiring 36,802 additional shares, according to a Form 13F filing.68d agoAgios Pharmaceuticals advanced AG-236 into Phase 2/3 development for polycythemia vera.82d agoAgios Pharmaceuticals licensed cevidoplenib for immune thrombocytopenia, diversifying its late-stage pipeline.82d ago